Response to comment on 'SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung'.

COVID-19 SARS-CoV-2 bronchoalvelolar coagulation computational biology fibrinolysis human systems biology

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
11 01 2022
Historique:
received: 25 10 2021
accepted: 24 11 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 15 1 2022
Statut: epublish

Résumé

Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients (Mast et al., 2021). These findings have been challenged based on issues with the samples (Fitzgerald and Jamieson, 2022). We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

Identifiants

pubmed: 35014952
doi: 10.7554/eLife.74951
pii: 74951
pmc: PMC8752086
doi:
pii:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL126974
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140025
Pays : United States

Commentaires et corrections

Type : CommentOn

Informations de copyright

© 2022, Mast et al.

Déclaration de conflit d'intérêts

AM receives research funding from Novo Nordisk and has received honoraria for serving on Novo Nordisk advisory boards, AW Receives research funding from Takeda and Bristol Myers Squibb, DG Receives research funding from Bayer and has received honoraria for serving on Anthos, Bristol-Myers Squibb, Ionis and Janssen advisory boards, MG, CA, JM, PJ, BA, DJ No competing interests declared

Références

RNA. 2020 Aug;26(8):903-909
pubmed: 32284352
Blood. 2020 Sep 10;136(11):1330-1341
pubmed: 32678428
J Clin Invest. 2020 Nov 2;130(11):6151-6157
pubmed: 32759504
PLoS One. 2020 Nov 11;15(11):e0241825
pubmed: 33175863
Blood. 2021 Jul 29;138(4):344-349
pubmed: 34075401
Nat Biotechnol. 2014 Sep;32(9):896-902
pubmed: 25150836
Elife. 2022 Jan 11;11:
pubmed: 35014954
Elife. 2021 Mar 08;10:
pubmed: 33683204

Auteurs

Alan E Mast (AE)

Versiti Blood Research Institute, Department of Cell Biology Neurobiology and Anatomy Medical College of Wisconsin, Milwaukee, United States.

Alisa S Wolberg (AS)

Department of Pathology and Laboratory Medicine and UNC Blood Research Center, Chapel Hill, United States.

David Gailani (D)

Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, United States.

Michael R Garvin (MR)

Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, United States.

Christiane Alvarez (C)

Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, United States.

J Izaak Miller (JI)

Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, United States.

Piet Jones (P)

University of Tennessee Knoxville, The Bredesen Center for Interdisciplinary Research and Graduate Education, Knoxville, United States.

Bruce Aronow (B)

Biomedical Informatics, Cincinnati Children's Hospital Research Foundation, University of Cincinnati, Cincinnati, United States.

Daniel Jacobson (D)

Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH